The Sinus Is the Victim, Pepsin Is the Perpetrator: Posterior Sinonasal Syndrome as the Etiological Precursor to Chronic Rhinosinusitis, Field Carcinogen of the Upper Aerodigestive Tract, and the Biological Imperative for Mucosal-Preserving Surgery

1. Introduction

Laryngopharyngeal reflux (LPR) — the retrograde flow of gastric contents above the upper esophageal sphincter into the laryngopharynx and beyond — has become one of the more consequential diagnoses in modern otolaryngology. Prevalence has increased approximately 4% per year since 1976. Otolaryngology visits attributable to LPR rose 500% between 1990 and 2001. A condition that was rarely encountered a generation ago now occupies a substantial portion of a busy ENT practice.[27]

For most of this period, the working model of LPR-driven injury centered on acid. That model was always incomplete. Laryngopharyngeal mucosa is damaged by as few as four acid reflux episodes per day — the esophageal mucosa tolerates fifty without visible injury. Acid suppression with proton pump inhibitors fails to resolve LPR symptoms in a substantial proportion of patients. pH monitoring studies have documented repeatedly that many LPR events occur at weakly acidic or non-acidic pH levels that would never trigger a standard probe event. The acid model explained some of what was observed clinically. It never explained all of it.[17]

The work of Johnston and colleagues, beginning in 2007, reframed the pathophysiology in a way that the acid model could not. Pepsin — the principal proteolytic enzyme of gastric refluxate — is actively internalized by upper airway epithelial cells through receptor-mediated endocytosis at neutral pH, trafficked to the trans-Golgi compartment where the acidic luminal environment reactivates its proteolytic activity, and then depletes the epithelial barrier proteins E-cadherin, carbonic anhydrase isoenzyme III, Sep70, and Sep53. That mechanism, and its extension to sinonasal tissue by Southwood and colleagues in 2015, is described in detail in Section 3 and Section 4.[1,2,3,6]

What the clinical literature has not adequately examined is why this epidemic arrived when it did. Three developments beginning in the mid-twentieth century transformed pepsin from a gastric enzyme with incidental upper airway exposure into a chronic mucosal pathogen delivered at historically unprecedented frequency. The obesity epidemic increased intragastric pressure mechanically, disrupted esophagogastric junction anatomy, and promoted the transient lower esophageal sphincter relaxations that drive refluxate above the upper esophageal sphincter — the GERD rate ratio rising from pre-1995 baseline to 1.51 by 2005–2009, tracking the obesity curve closely. The high-fat Western diet independently relaxed the lower esophageal sphincter through a cholecystokinin-mediated mechanism, adding a pharmacological insult to the mechanical one. Less recognized than either of these, FDA food acidification mandates beginning in the late 1970s ensured that nearly every commercially bottled or canned beverage in the American food supply — with the exception of still water — is acidified to a pH of 2.8–4.4. The esophageal adenocarcinoma incidence data from SEER records the oncologic consequence: a 767% increase from 1973 baseline, averaging 5.1% annual growth, in the cancer that sits at the downstream end of the same reflux-pepsin pathway.[27]

Central to this paper is a clinical argument that has not previously been articulated in the rhinology literature. Posterior sinonasal syndrome (PSS) is the direct upstream precursor to refractory chronic rhinosinusitis in a defined and identifiable patient population. PSS is not a variant of CRS. It is not a comorbidity. It is the mucosal priming condition — created by pepsin endocytosis in posterior nasal columnar epithelium, progressing silently over years — that makes the posterior nasal mucosa susceptible to the inflammatory cascade that produces clinical CRS when any sufficient secondary trigger arrives. The sequence is fixed: pepsin injury first, threshold lowering second, trigger third, clinical CRS fourth. The CRS in the PSS patient is not the primary disease. It is the declared endpoint of a process that began upstream, in the posterior nasal mucosa, years or decades before the patient presented with symptoms that met the diagnostic criteria for sinusitis. Treating CRS without identifying and addressing the PSS that precedes and causes it is treating the consequence while the cause continues to operate. This is why the PSS-CRS patient fails every treatment the guideline recommends: the guideline treats CRS. The patient has PSS. The sinus is the victim. Pepsin is the perpetrator.

This paper proposes a unified model connecting these disparate bodies of evidence. Pepsin endocytosis in upper airway epithelium is not a tissue-specific event limited to the larynx — it is a universal consequence of LPR across the entire upper aerodigestive tract. The clinical manifestation of this injury varies by tissue type and anatomical position within the reflux concentration gradient. Understanding this model has direct implications for the management of refractory CRS, the cancer risk counseling of LPR patients, and the design of the confirmatory studies that could formally establish one of the most clinically significant mechanisms in upper airway medicine.

2. The Anatomical Concentration Gradient: A Foundation for the Model

The path of LPR refluxate follows a defined anatomical sequence. Gastric contents that overcome the lower esophageal sphincter ascend through the esophagus. Those that additionally overcome the upper esophageal sphincter enter the hypopharynx first, contact the laryngeal inlet, ascend to the nasopharynx, and may eventually reach the posterior nasal cavity and paranasal sinuses. At each successive station, the refluxate is progressively diluted by salivary bicarbonate, mucosal secretions, and gravitational dispersion.

This anatomy creates a concentration gradient for pepsin that is highest at the hypopharynx and larynx and lower — but still clinically significant — at the nasopharynx and nasal cavity. The significance of this gradient to the argument that follows cannot be overstated. Pepsin does not travel from the nose downward to the larynx. It travels from the stomach upward, reaching the larynx before the nose. A patient in whom nasal pepsin is detectable at endocytosis-sufficient concentrations is, by anatomical necessity, a patient in whom laryngeal and hypopharyngeal pepsin burden is at least as great and almost certainly greater.

Detection of pepsin in nasal lavage fluid or nasal tissue from a CRS patient is therefore not simply evidence of a sinusitis-LPR association. It is evidence that pepsin endocytosis is occurring throughout that patient’s upper airway, at higher concentrations in the tissues anatomically closer to the source. The nasal cavity is the distal sentinel of a process that is more intense at the larynx and hypopharynx. That framing matters for everything that follows.

3. The Endocytosis Mechanism Is Not Larynx-Specific

Johnston’s foundational 2007 paper established that pepsin uptake by laryngeal epithelial cells is receptor-mediated, using electron microscopy to demonstrate co-localization of pepsin with transferrin — a classical marker of receptor-mediated endocytosis — in intracellular vesicles. Subsequent work confirmed that the internalized pepsin is trafficked to late endosomes and the trans-Golgi network, where acidic luminal pH of approximately 4 to 5 reactivates its proteolytic activity.[1,4]

Johnston’s group noted that it is unlikely there is a specific biologic receptor for pepsin, proposing instead that pepsin exploits or piggybacks another receptor-ligand complex, dysregulating its normal physiological function. The receptor has not been definitively identified in the published literature. What has been established is that the uptake pathway uses clathrin-mediated endocytosis — one of the most universal and fundamental cellular processes in human biology, operating in every nucleated cell for nutrient uptake, growth factor signaling, and membrane recycling. Clathrin-mediated endocytosis is not a larynx-specific mechanism.[1]

Southwood and colleagues extended the pepsin damage story to human nasal epithelial cells in 2015. Using electron microscopy, they demonstrated mitochondrial damage in pepsin-treated nasal epithelial cells that was not present in controls — the same mitochondrial fingerprint documented in pepsin-treated laryngeal cells. Mitochondrial damage at neutral pH, where pepsin is enzymatically inactive on the cell surface, is mechanistically explained only by intracellular reactivation. Surface contact with inactive pepsin at neutral pH does not damage mitochondria. Pepsin must be inside the cell, in an acidic compartment, to produce this pattern.[6]

This inference is further supported by Samuels and colleagues’ counterintuitive finding that pepsin endocytosis is more prominent at neutral pH than at weakly acidic pH. The more alkaline the refluxate, the more efficiently pepsin is internalized. For patients on high-dose PPI therapy, this has a direct and uncomfortable implication: acid suppression that neutralizes refluxate does not suppress pepsin and may optimize the pH conditions for endocytosis rather than preventing it.[7]

Taken together, the available evidence supports the conclusion that pepsin endocytosis is a property of upper airway epithelial cells generally — operating through a universal clathrin-dependent mechanism and producing the same intracellular damage signature, mitochondrial dysfunction, depletion of protective proteins, and activation of inflammatory cytokine pathways, in both laryngeal and nasal cell types.

4. Tissue-Specific Endpoints: Why the Same Injury Produces Different Diseases

If pepsin endocytosis operates in both laryngeal and nasal epithelial cells and produces similar intracellular damage in both, why does the clinical literature describe laryngeal carcinoma as an endpoint of LPR while CRS — not sinonasal malignancy — is the dominant upper airway disease associated with reflux? The answer lies in the fundamental biological differences between the two tissue types.

Laryngeal epithelium is stratified squamous — histologically identical to esophageal and oropharyngeal epithelium. Squamous epithelium’s characteristic response to chronic sublethal injury is dysplasia, and the well-established pathological sequence of chronic irritation to squamous metaplasia to dysplasia to carcinoma in situ to invasive carcinoma is the same pathway observed in Barrett’s esophagus progression, HPV-driven oropharyngeal carcinoma, and tobacco-associated head and neck cancer. Pepsin-driven depletion of E-cadherin, Sep70, and carbonic anhydrase in laryngeal squamous cells creates the compromised cellular environment in which this dysplastic pathway is facilitated. Johnston’s group has demonstrated that pepsin treatment of laryngeal and hypopharyngeal cell lines produces NF-kB activation, upregulation of TRAIL and BCL2A1, promotion of anchorage-independent growth and cell migration, and changes in miRNA profiles identical to those observed in head and neck squamous cell carcinoma — and critically, pepsin has been identified within laryngeal and hypopharyngeal carcinoma tissue itself, establishing its presence not merely as a risk association but as a molecular participant at the tumor site. That same tissue-level detection has been independently confirmed at the proximal end of the reflux gradient: Li et al. identified pepsin in 85.7% of nasopharyngeal carcinoma tissue versus 17.2% of chronic nasopharyngitis controls — the NPC finding that, paired with Johnston’s laryngeal tissue detection, constitutes the two-site molecular fingerprint of pepsin as a field carcinogen operating across the full upper aerodigestive mucosal surface.[5,13,16]

Sinonasal epithelium is pseudostratified ciliated columnar respiratory epithelium — structurally and immunologically distinct. Respiratory epithelium does not characteristically undergo squamous dysplasia under chronic inflammatory stress. Its pathological response to persistent injury is chronic mucosal inflammation, goblet cell hyperplasia, ciliary dysfunction, and the self-perpetuating inflammatory cycle that defines CRS. Southwood’s pepsin-treated nasal epithelial cells produced a pro-inflammatory cytokine signature including IL-8 that overlaps precisely with the CRS inflammatory profile. Sinonasal malignancy is rare not because the posterior nasal mucosa is protected from pepsin, but because respiratory epithelium does not undergo the dysplastic transformation pathway that squamous epithelium follows under the same intracellular insult.[6]

This tissue-type specificity reconciles the epidemiology with the proposed model. CRS affects approximately 30 million Americans — roughly 10% of the adult population. Laryngeal cancer produces approximately 13,000 new cases per year in the United States. The 2,000-fold difference in prevalence does not argue against a shared upstream mechanism. It argues precisely for tissue-specific endpoints from that shared mechanism.

5. The Cofactor Model: Why Not All Patients Progress to Laryngeal Cancer

The proposed model does not claim that LPR causes laryngeal cancer in all exposed patients, or even in most. The meta-analysis by Luo et al. (2018), drawing on 18 case-control studies, found an odds ratio of 2.47 for laryngeal malignancy in patients with reflux disease — elevated, but far from deterministic. In the subset of studies examining LPR specifically rather than GERD broadly, the odds ratio was 3.09. A 3-fold elevation in risk in a disease with a baseline annual incidence of 2.5 per 100,000 still produces a rare outcome in absolute terms.[11]

This pattern — a mechanism present in many, a catastrophic outcome in few — is characteristic of co-carcinogenesis. Tobacco is the strongest established risk factor for laryngeal cancer; the vast majority of smokers never develop it. HPV infects most sexually active adults; oropharyngeal carcinoma remains rare. Hepatitis C virus causes hepatocellular carcinoma in a fraction of chronically infected patients. In each of these cases, the carcinogenic agent is necessary to explain the elevated risk but not sufficient to produce disease on its own.

The cofactors that may determine which LPR patients progress from pepsin-driven squamous cell injury to dysplasia and carcinoma include cumulative lifetime exposure to pepsin endocytosis events — which determines the degree of protective protein depletion — tobacco and alcohol use, individual genetic variation in DNA repair capacity and immune surveillance, and the degree to which the upper esophageal sphincter is incompetent, which determines how consistently refluxate reaches the supraglottic structures.

The Lewin et al. 2003 prospective study is instructive. Eighty-five percent of patients with premalignant or early laryngeal carcinomas had documented LPR on 24-hour pH monitoring, and critically, no significant association was found between the level of LPR and histologic stage or smoking status. Heartburn did not predict LPR. LPR appears to operate as a background facilitator — present across the spectrum from dysplasia to invasive cancer, not correlated with stage because it is a permissive condition rather than a staging variable.[12]

A critical methodological limitation of the Lewin study and of the broader LPR-laryngeal cancer literature deserves explicit acknowledgment. The 24-hour pH monitoring used to identify LPR detects acid — specifically, episodes in which hypopharyngeal or esophageal pH drops below a defined threshold. It does not detect pepsin. A patient whose LPR is predominantly non-acidic would read as LPR-negative on 24-hour pH monitoring despite having active pepsin in their hypopharynx undergoing receptor-mediated internalization into laryngeal squamous cells. The 85% prevalence of LPR in Lewin’s premalignant and early carcinoma population, measured by acid detection, is almost certainly an underestimate of the true pepsin exposure prevalence. The parallel finding at the proximal end of the reflux gradient — Li et al.’s detection of pepsin in 85.7% of NPC tissue — reinforces this conclusion: if pepsin is present in malignant tissue at both the distal high-concentration station (larynx) and the proximal lower-concentration station (nasopharynx), the field carcinogen model predicts that pH-based studies are systematically underestimating pepsin’s carcinogenic role across the entire upper aerodigestive tract.

In summary: pepsin endocytosis in laryngeal squamous cells appears to be necessary but not sufficient for malignant transformation. It creates a compromised intracellular environment in which carcinogenic cofactors can complete the transformation. The low absolute incidence of laryngeal cancer in the LPR population reflects the requirement for multiple cofactors, not the absence of the upstream mechanism.

6. The Developmental Hypothesis: Childhood LPR as the Origin of Adult CRS

The mechanism described in the preceding sections does not begin in adulthood. The evidence suggests it begins in childhood — and that the accumulated subclinical posterior nasal mucosal injury from years of pediatric LPR is the missing etiology of the slow progressive mucosal activation that eventually presents as adult CRS.

The evidentiary anchor for this claim is the landmark 2002 study by Tasker and colleagues, published in The Lancet, which detected pepsin and pepsinogen in 83% of middle ear effusion fluid samples from children undergoing myringotomy for otitis media with effusion. The middle ear communicates with the nasopharynx via the Eustachian tube. Pepsin in the middle ear requires pepsin in the nasopharynx first. The Tasker finding established that in a substantial majority of children with recurrent otitis media with effusion — one of the most common pediatric conditions managed by otolaryngologists — gastric refluxate is routinely reaching the nasopharynx and posterior nasal cavity.[18]

If the pepsin endocytosis mechanism operates in posterior nasal respiratory epithelium as proposed in Section 3 and Section 4, then these children are not merely experiencing episodic surface irritation. They are experiencing receptor-mediated internalization of pepsin into posterior nasal epithelial cells, with the same downstream consequences demonstrated in adult nasal epithelial cells in vitro. The difference is duration: a child with LPR beginning in infancy and persisting through adolescence may accumulate a decade or more of subclinical posterior nasal mucosal injury before any clinical presentation of sinusitis occurs.

This framing resets the natural history of CRS entirely. The current clinical model treats CRS as a disease of adult onset — something that develops in the third, fourth, or fifth decade, typically attributed to a combination of anatomic factors, allergic sensitization, and infectious history. The question clinicians ask is: why does this adult have chronic sinusitis? The developmental hypothesis asks a different question: what was happening in this person’s posterior nasal mucosa at age three, age eight, age fourteen?

The slow, progressive character of CRS development is precisely what one would expect from subclinical cumulative injury spanning years to decades. Posterior nasal mucosal cells damaged by intermittent pepsin endocytosis do not immediately fail — they function in a progressively compromised state, their activation threshold dropping lower until what was subclinical injury crosses into the recognized clinical syndrome of chronic rhinosinusitis.

In my 30 years of rhinologic practice, the most challenging and least understood CRS subset is the patient with severe, progressive posterior mucosal inflammation who has anatomically normal or near-normal sinuses on CT, well-controlled allergic disease, no significant infectious history, and yet fails every intervention offered. These are patients whose disease appears to have no adequate proximate cause in adulthood because the cause is not proximate — it is distal in time, rooted in a childhood of unrecognized and untreated LPR silently injuring the posterior nasal mucosa year after year.

The clinical implications move in two directions. Looking backward at adult CRS patients, a detailed history of childhood ear disease — specifically recurrent otitis media with effusion, which the Tasker data identifies as a surrogate marker for nasopharyngeal pepsin exposure — becomes a potentially informative element of the rhinologic intake. A 45-year-old with refractory posterior CRS who had multiple sets of pressure equalization tubes as a child may be telling you, without knowing it, that their posterior nasal mucosal priming began in kindergarten. Looking forward at pediatric patients, children with LPR and recurrent otitis media with effusion deserve an upstream diagnosis and upstream management — not merely tubes and adenoidectomy for the downstream tissue consequences of a process that is not being addressed at its source.

A second subset of patients appears to follow a distinct course: posterior nasal mucosal injury accumulates at a faster rate, reaching a primed pre-inflammatory state relatively early, then waiting. The threshold is crossed not by slow accumulation but by a discrete precipitating event delivering sufficient additional inflammatory load to a tissue already positioned at the edge of clinical disease. The candidates for that triggering event are familiar to any rhinologist — a first significant allergic sensitization, a severe bacterial sinusitis, an occupational irritant exposure, the immune shifts of early pregnancy. What makes this subset clinically distinctive is not the nature of the trigger. It is the speed and severity of the response. Most patients who sustain a first sinus infection recover. The patient in this subset does not. Their disease goes chronic rapidly, it is immediately posterior-predominant, and they arrive asking why they have not responded to treatments that resolve the condition in everyone else around them. The answer is that their posterior nasal mucosa was not normal at the moment the trigger arrived. It had been subclinically injured for years, its activation threshold already at the edge, and the precipitating event did not cause their CRS — it revealed it.

6.1. The Nasopharyngeal Lymphoid Cascade: Adenotonsillar Inflammation as a Parallel Endpoint

The posterior nasal mucosa is not the only nasopharyngeal tissue exposed to pepsin-laden refluxate in children with LPR. Waldeyer’s ring — the circumferential arrangement of lymphoid tissue comprising the adenoid, the palatine tonsils, and the lingual tonsil — sits at the anatomical crossroads where ascending refluxate, descending nasal secretions, and inspired air all converge. If pepsin reaches the nasopharynx in sufficient concentration to be endocytosed by posterior nasal respiratory epithelial cells, it is simultaneously bathing the adenoid and, via the oropharynx, the palatine tonsils.

This is not inferential. Pepsin has been detected in adenoid and tonsillar tissue in published studies. Ozdek and colleagues demonstrated pepsin and pepsinogen in adenoid tissue from children undergoing adenoidectomy, with significantly higher concentrations in children with recurrent disease than in controls. Agackiran and colleagues found similar findings in tonsillar tissue. The adenoid and tonsils are not passive bystanders — they are repeatedly exposed to a proteolytic enzyme capable of receptor-mediated internalization and progressive depletion of the barrier proteins and stress response proteins that protect mucosal surfaces from chronic inflammatory injury.[19,20]

Chronic pepsin exposure of nasopharyngeal lymphoid tissue, I propose, drives the adenotonsillar hypertrophy and recurrent inflammatory cycles that define the pediatric upper airway surgical patient. Pepsin endocytosis in lymphoid epithelium activates inflammatory cytokine cascades, impairs barrier function, and creates a chronically inflamed tissue that responds to each subsequent viral or bacterial exposure with exaggerated, prolonged inflammation. The clinical result — enlarging adenoids, recurrent tonsillitis, and the hypertrophic adenoid that obstructs the Eustachian tube orifice — is the predictable tissue-level consequence of repeated pepsin-driven intracellular injury in lymphoid epithelium.

The mechanical consequence of adenoid hypertrophy closes the loop with the Tasker middle ear finding. An enlarged, inflamed adenoid physically obstructs the Eustachian tube orifice, impairing middle ear pressure equalization and creating the negative pressure environment that draws nasopharyngeal fluid — including pepsin-containing refluxate — into the middle ear space. Pepsin in the middle ear may therefore arrive via two pathways: direct Eustachian tube reflux of nasopharyngeal pepsin, and passive effusion into a middle ear rendered dysfunctional by pepsin-driven adenoid hypertrophy. Both pathways originate from the same upstream source.

The pediatric upper airway surgical triad — pressure equalization tubes, adenoidectomy, and tonsillectomy — represents three separate surgical responses to what may, in a significant subset of patients, be a single upstream problem: untreated or undertreated LPR driving pepsin-mediated inflammation throughout Waldeyer’s ring and the posterior nasal mucosa. The child who receives a third set of tubes, an adenoidectomy at age seven, and a tonsillectomy at age nine may be a child in whom the surgical interventions are addressing the downstream tissue manifestations of pepsin injury while the upstream pepsin exposure continues uninterrupted. This does not argue against surgical intervention — tubes, adenoidectomy, and tonsillectomy remain appropriate treatments for the immediate problems they address. It argues that surgical intervention without concurrent LPR evaluation may be treating the result while leaving the cause active.

The population-level surgical trend data make this epidemiologically urgent. Erickson and colleagues documented that adenotonsillectomy rates rose from 369 per 100,000 person-years in the early 1970s to 638 per 100,000 by 2000–2005 — a 73% increase over three decades. Parker and Walner’s analysis found the absolute number of children undergoing adenotonsillar surgery increased from approximately 441,870 in 1996 to 695,029 in 2006, a 57% increase in ten years. The indication driving this growth was upper airway obstruction and sleep-disordered breathing, rising from 12% of procedures in 1970 to 77% by 2005. Upper airway obstruction is the clinical endpoint of the hypertrophic adenotonsillar tissue that this model predicts as the downstream consequence of chronic pepsin-driven lymphoid inflammation. Zhou and colleagues found that 69.77% of salivary samples from children with adenoid hypertrophy tested pepsin-positive, with a positive correlation between pepsin intensity and adenoid hypertrophy grade. The mechanistic chain from upstream pepsin exposure to downstream surgical intervention is established in the biology.[29,30,31]

7. Clinical Implications

7.1. The CRS Patient with LPR Is a Laryngeal Surveillance Patient

The most immediately actionable implication of this model is the reframing of the LPR-positive CRS patient. If nasal pepsin detection implies laryngeal pepsin endocytosis at equal or greater concentrations, then a patient presenting with refractory posterior CRS and documented or suspected LPR is a patient in whom intracellular pepsin damage is almost certainly active at the level of the larynx and hypopharynx. This does not mean that patient will develop laryngeal cancer — the cofactor model argues they may well not. It means that careful laryngoscopic evaluation of the supraglottis and posterior commissure is warranted, and that a high index of suspicion for laryngeal dysplasia is appropriate in patients with long-duration refractory LPR, particularly those with tobacco or alcohol history. The anatomical gradient model further demands nasopharyngeal attention: Li et al.’s detection of pepsin in 85.7% of NPC tissue confirms that the proximal end of the reflux gradient carries the same tissue-level pepsin burden as the larynx, and nasopharyngoscopy with attention to the fossa of Rosenmüller should be a standard component of the complete surveillance examination in the high-pepsin-burden patient.

7.2. Surgical and Procedural Management in PSS: An Integrated Framework

The framework proposed in this paper does not challenge the surgical and procedural management of CRS broadly — it argues that the correct surgical approach in the PSS subset is fundamentally different from the aggressive tissue-resecting paradigm that has become the default in tertiary rhinologic practice. This distinction matters because PSS patients are overrepresented in the refractory CRS population that presents for revision surgery. Applying the same surgical approach to PSS-driven posterior CRS that is appropriate for polyp-dominant, anatomically obstructive, or fungal CRS is not neutral — it is actively harmful, for reasons the biology of pepsin-driven posterior mucosal injury makes precise.

When the primary driver of CRS is pepsin-induced intracellular injury that has lowered the posterior nasal mucosal inflammatory threshold, the sinus is a victim of upstream molecular disease. Surgery that removes the mucosal substrate — wide antrostomy creating goblet cell-depleted, mucociliary transport-disrupted maxillary sinuses; middle turbinate resection eliminating structural and physiological baffling; ethmoid marsupializtion creating squamous metaplastic patchwork healing — does not address the intracellular mechanism and destroys the tissue architecture that pepsin-directed treatment requires intact in order to produce mucosal recovery.

The appropriate surgical role in the PSS patient is mucosal preservation: balloon sinuplasty restoring ostial patency without mucosal resection, natural ostium-preserving approaches consistent with Setliff’s small hole surgery principles, and procedures that address anatomic, physiologic, and neural contributors to posterior disease without converting recoverable respiratory epithelium into permanent squamous metaplastic surfaces.

Balloon sinuplasty is the surgical expression of the correct biological logic in the PSS patient. It restores ostial patency through catheter-based dilation of the natural ostium without mucosal resection, without bone removal at the ostium margins, and without disrupting the ciliary continuity that mucociliary transport requires. Goblet cell populations, secretory IgA production, innate immune mucosal coating, and the respiratory columnar epithelial architecture that pepsin-directed treatment depends on are preserved intact. In the PSS patient with ongoing pepsin delivery, balloon sinuplasty leaves the posterior nasal and sinonasal mucosal substrate in a state where — if pepsin burden is simultaneously reduced — it retains the biological capacity to recover.

Functional endoscopic sinus surgery remains appropriate where the primary driver is genuinely anatomical: significant polypoid disease producing mechanical obstruction, anatomic variants generating contact-point inflammation, or fungal disease requiring surgical debridement. In the PSS patient whose posterior CRS is driven by pepsin-induced mucosal priming rather than anatomical obstruction, the indication for aggressive tissue-resecting FESS does not exist.

Turbinate reduction restores nasal airflow and reduces nasal resistance in PSS patients whose turbinate hypertrophy reflects both anatomic predisposition and pepsin-driven posterior mucosal inflammatory burden. The clinical consequences of improved nasal airflow extend substantially beyond sinus symptom scores. Restored nasal breathing improves sleep architecture, reduces sleep-disordered breathing, and addresses the brain fog and sleep disturbance that a significant subset of PSS patients describe as among their most debilitating symptoms.

Eustachian tube balloon dilation addresses the posterior nasopharyngeal inflammatory consequence of pepsin-driven mucosal injury at the Eustachian tube orifice. Chronic nasopharyngeal mucosal inflammation in PSS patients impairs Eustachian tube function, reduces pressure equalization capacity, and contributes to the ear fullness, pressure sensation, and muffled hearing that accompany posterior CRS in a significant proportion of patients. Its durability in PSS patients is optimized when combined with upstream pepsin-directed management.

Neuromodulation of the posterior nasal nerve requires precise anatomical distinction between the currently available procedures. Cryotherapy via ClariFix and radiofrequency neuromodulation via RhinAer both target the posterior nasal nerve at the sphenopalatine foramen region in the posterior lateral nasal wall. Both downregulate posterior nasal nerve activity in the immediate nasal cavity territory. Their treatment zone, however, does not extend to the nasopharynx.

The Neumark procedure delivers radiofrequency neuromodulation at the sphenopalatine foramen region and then extends treatment with two additional delivery points in the nasopharynx that neither ClariFix nor RhinAer reaches. This is the defining clinical distinction of the Neumark procedure: it encompasses the established foraminal treatment zone and expands beyond it into the nasopharyngeal peripheral branch network that innervates the posterior nasal mucosa in its deepest territory, the nasopharynx itself, and the autonomic supply to the Eustachian tube orifice. The result is a substantially greater total surface area of radiofrequency neuromodulation delivered into the posterior nasal and nasopharyngeal nerve field in a single treatment session. The procedure is designed for office-based delivery under local anesthesia, making it accessible to a wider range of providers and facilitating the repeat treatment sessions that a reversible neuromodulatory approach permits.

For the PSS patient, whose disease is concentrated in exactly the nasopharyngeal territory that the Neumark procedure’s additional treatment points specifically reach, Neumark is the neuromodulation procedure whose anatomical coverage matches the PSS disease distribution. Pepsin endocytosis in posterior nasal and nasopharyngeal epithelial cells drives chronic cytokine activation and mucosal inflammation that continuously hyperstimulates the posterior nasal nerve branches distributing through that territory. Neumark, by downregulating those nasopharyngeal nerve branches, may interrupt one of the neural amplification loops that perpetuates PSS independent of ongoing pepsin exposure.

7.3. Pepsin-Directed Medical Management: A Practical Treatment Framework

There is currently no formally established, guideline-endorsed treatment protocol specifically for pepsin-driven CRS or PSS. This absence is a direct consequence of the diagnostic infrastructure gap described in Section 9 — without a validated clinical assay for nasal pepsin, there is no recognized patient population around which to build a treatment protocol. What follows represents the best available evidence-based framework for pepsin-directed management, synthesized from the LPR literature, the Koufman dietary work, the Johnston mechanistic studies, and 30 years of clinical observation in a high-volume rhinology practice.

Dietary modification is the most mechanistically grounded and immediately accessible intervention. The low-acid, low-fat diet developed and refined by Koufman and colleagues reduces both gastric acid production and gastric pepsin secretion at the source. The primary dietary triggers to eliminate are coffee, alcohol, carbonated beverages, citrus, tomatoes, chocolate, mint, and high-fat foods. These do not merely increase reflux frequency — several directly stimulate gastric pepsin secretion and reduce lower esophageal sphincter tone, increasing both the volume and proteolytic activity of the refluxate reaching the upper airway. Dietary modification is the upstream intervention that reduces the pepsin burden available for endocytosis before it reaches the posterior nasal mucosa and larynx. Patient compliance with dietary modification is the single most important determinant of treatment response in pepsin-driven CRS, and the counseling investment required to achieve it is substantially higher than prescribing a medication.[28]

Alkaline water at pH 8.8 or higher is a mechanistically grounded adjunct to dietary modification, but its precise mechanism and anatomical scope require accurate framing to avoid clinical misapplication. Koufman’s group demonstrated that pH 8.8 water irreversibly denatures pepsin — permanently eliminating its proteolytic activity through alkaline hydrolysis. This distinction matters: pepsin remains structurally stable and reactivatable at pH up to 8.0, so only water at or above pH 8.8 achieves irreversible rather than merely reversible inactivation. The observation that endocytosis is maximized at neutral pH 7.0 — when pepsin is enzymatically silent but structurally intact — explains precisely why conventional water and PPI-alkalinized refluxate fail to prevent pepsin injury: they create the neutral pH environment that maximizes cellular uptake without reaching the 8.8 threshold required for irreversible denaturation. High-dose BID proton pump inhibitor therapy similarly fails to solve this problem: PPI-suppressed gastric pH typically reaches 4–6, which renders pepsin inactive but not denatured, and once pepsin is internalized into the late endosomal and trans-Golgi compartment where pH drops to approximately 5.5, it reactivates intracellularly regardless of extracellular acid suppression.[25]

For PSS patients whose primary pepsin burden is posterior nasal and nasopharyngeal, swallowed alkaline water addresses the pharyngeal and laryngeal LPR injury gradient but does not reach the nasal cavity or nasopharynx by the swallowing route. Alkaline saline nasal lavage directed posteriorly toward the choana is the delivery vehicle for the PSS-specific anatomical target. Both interventions are appropriate and complementary in the PSS patient, and both should be prescribed explicitly.

Alginate-based barrier therapy is the most mechanistically targeted anti-pepsin treatment currently available and the most underutilized in United States clinical practice. Sodium alginate preparations form a physical raft on the surface of gastric contents immediately after ingestion, mechanically preventing refluxate from reaching the upper esophageal sphincter and physically trapping pepsin within the gastric compartment before it can reflux into the upper airway. Unlike acid suppression, alginates act on pepsin directly — binding it at the source regardless of refluxate pH. Alginate preparations available in the United States should be used after meals and at bedtime in PSS patients with suspected or confirmed pepsin-driven disease.

Proton pump inhibitors retain a role in PSS management for patients with concurrent acid-driven esophageal disease, where they are appropriate and necessary. However, PPIs do not suppress pepsin and may paradoxically optimize endocytosis conditions by raising refluxate pH toward neutral. PPIs should be used at the lowest effective dose in PSS patients and should never be presented to the patient as the primary treatment for their posterior mucosal disease.

Posterior nasal saline irrigation — high-volume, directed posteriorly toward the nasopharynx — reduces surface pepsin dwell time in the posterior nasal cavity and nasopharynx by mechanical washout. Irrigation technique matters significantly in PSS patients: standard anterior-directed irrigation inadequately reaches the posterior nasal cavity and nasopharynx where pepsin deposition is concentrated. High-volume squeeze bottle or pulsatile irrigation directed toward the posterior choana, performed twice daily, is the appropriate technique.

Head of bed elevation — 6 to 8 inches — reduces nocturnal LPR, which is mechanistically the most damaging reflux pattern in PSS. During sleep, salivary bicarbonate production essentially ceases, swallowing frequency drops dramatically, and refluxate that reaches the upper airway dwells at mucosal surfaces far longer than during waking hours. Gravity elevation of the head of bed — not pillow elevation, which flexes the neck and may worsen reflux — reduces this nocturnal exposure substantially.

7.4. The Limitation of Acid Suppression Alone

Effective LPR management in PSS requires pepsin containment, not just acid suppression. Alginates physically bind pepsin in the refluxate before it reaches the upper airway. Dietary modification eliminates the triggers that stimulate pepsin secretion at the source. PPI therapy addresses a co-traveler, not the driver, and its limitations are mechanistically predictable from the endocytosis model described in Section 3.

7.5. The Pediatric Surgical Patient Deserves an LPR Evaluation

The adenotonsillar cascade described in Section 6.1 has one immediate clinical implication that requires no new research to implement: the child with recurrent, refractory, surgically-resistant upper airway disease deserves a systematic LPR evaluation before additional surgical intervention is planned. Not every child with a first ear infection — the child who needs a third set of tubes, whose adenoid regrows, who returns for a fourth procedure. That child deserves the question: is there an upstream pepsin-driven process that surgery is not reaching?

In my experience, LPR in children is systematically underdiagnosed because its presentation differs from adult reflux disease. Children with LPR rarely complain of heartburn. They present with chronic cough, throat clearing, noisy breathing, and recurrent respiratory infections — the exact upper airway surgical indications described above. The absence of classic GERD symptoms in a child with recurrent otitis, adenoid hypertrophy, and tonsillar disease should not be interpreted as the absence of reflux. It should prompt consideration of LPR as the silent upstream driver.

7.6. PSS and the 2025 AAO-HNS Clinical Practice Guideline: The Missing Inflammatory Driver

The 2025 AAO-HNS clinical practice guideline update on chronic rhinosinusitis represents the most authoritative current statement from the specialty on CRS management. The guideline makes three antibiotic-related recommendations that collectively reframe CRS as primarily inflammatory rather than primarily infectious: watchful waiting is recommended for acute bacterial rhinosinusitis unless symptoms have persisted a minimum of 14 days; when antibiotics are prescribed, a 5 to 7 day course is now recommended; and saline irrigation followed by topical intranasal corticosteroids — not antibiotics — is positioned as the primary first-line treatment for CRS. These recommendations are correct and overdue.[23]

However, the guideline’s inflammation-focused framework reaches a ceiling in the PSS patient that it does not yet have the mechanistic vocabulary to explain. The PSS patient has already been irrigating with saline. They have already been using topical intranasal corticosteroids daily, often for years. Their posterior mucosal inflammation persists despite faithful adherence to exactly the treatment the 2025 guideline recommends — because those treatments, however appropriate, are operating at the wrong level. Saline irrigation mechanically removes surface debris. Topical corticosteroids suppress cytokine signaling at the epithelial surface. Neither penetrates the cell. Neither reverses pepsin-driven mitochondrial damage. Neither restores the E-cadherin, carbonic anhydrase isoenzyme III, and stress proteins that pepsin endocytosis has progressively depleted from posterior nasal epithelial cells over years or decades.

The PSS patient who has exhausted the 2025 guideline’s treatment ladder is the patient for whom the guideline has no remaining answer — because the guideline does not yet recognize pepsin-driven intracellular injury as a distinct inflammatory mechanism in CRS. Allergy and anatomy have long been recognized as the two dominant modifiable contributors to CRS inflammation. Pepsin-driven posterior nasal mucosal injury is the third inflammatory driver — one that operates independently of allergy, independently of anatomy, and independently of infection. PSS is the clinical name for the CRS phenotype in which this third driver is dominant.

8. Gaps in the Evidence and Required Studies

This model is a hypothesis grounded in existing peer-reviewed data. Several confirmatory studies are required before it can be considered established.

The single most immediately practice-changing priority this paper identifies is the development and clinical validation of a quantitative posterior nasal lavage pepsin assay. The technology base exists: the monoclonal antibody platform developed from Johnston’s work and commercialized in the Peptest salivary lateral flow assay could be adapted to nasal lavage matrix with appropriate validation studies. What does not exist is a validated, standardized, clinically accessible office-based tool that a rhinologist could deploy at the time of nasal endoscopy — collecting a posterior nasal aspirate, processing by validated ELISA with established reference ranges, and receiving back a quantitative pepsin concentration result that distinguishes no exposure, low-level exposure, clinically significant PSS-range exposure, and high-burden cancer-risk-stratifying exposure. The validation study is straightforward in design: collect posterior nasal lavage samples prospectively from patients with PSS-pattern posterior CRS, anterior-predominant CRS, LPR without CRS, and normal controls; measure pepsin concentration by validated ELISA; correlate with symptom severity scores, endoscopic findings, and treatment response to pepsin-directed therapy. Without this assay, PSS remains a clinical and inferential diagnosis. With it, PSS becomes a laboratory-confirmable diagnosis with an objective quantitative measure of disease burden.

The following confirmatory studies address the mechanistic and clinical gaps that precede or accompany assay validation, organized by priority tier.

Tier 1 studies are executable in a high-volume rhinology practice without requiring basic science infrastructure. Study 2: Posterior nasal biopsy histopathology and pepsin immunohistochemistry in PSS — the single most critical mechanistic gap in this paper. Design: prospective case series with controls. Posterior nasal mucosal biopsy at time of endoscopy in PSS patients, anterior-predominant CRS patients, and normal controls. Primary outcome: prevalence of intracellular pepsin in posterior nasal columnar epithelium in PSS versus controls. A positive result transforms the PSS mechanism from strongly inferred to established. Study 3: Retrospective surgical history cohort study testing the developmental hypothesis using existing practice records — comparing adult PSS patients, anterior-predominant CRS patients, and normal controls on childhood surgical history including PE tube insertions, adenoidectomy, and tonsillectomy. Study 4: Laryngoscopic survey of PSS patients confirming that posterior nasal mucosal injury in PSS is accompanied by laryngoscopic evidence of pepsin-driven injury at the higher-concentration end of the same reflux gradient. Study 7: Prospective pepsin-directed PSS treatment trial with pre-post comparison and matched controls, measuring symptom severity score change, posterior nasal endoscopic mucosal appearance, and nasal lavage pepsin concentration at six and twelve months.

Tier 2 studies require academic pathology infrastructure or multi-site collaboration. Study 5: Pepsin immunohistochemistry in sinonasal carcinoma tissue — the most important named gap in the field cancerization section, directly testing whether pepsin is present in sinonasal SCC and adenocarcinoma tissue and providing the first direct tissue evidence connecting pepsin to sinonasal malignancy. Study 6: Squamous metaplasia characterization in post-FESS versus post-balloon sinuplasty maxillary sinus mucosa at one year — the direct tissue-level test of the surgical philosophy argument.

Tier 3 studies test the developmental and field cancerization hypotheses at population scale. Study 9: Administrative claims database analysis of pediatric surgical history and adult CRS, testing the developmental hypothesis using existing insurance claims data. Study 10: Longitudinal LPR exposure and CRS incidence cohort following LPR-confirmed adults without baseline CRS for five years, with incident CRS diagnosis compared to matched non-LPR controls.

9. The Diagnostic Infrastructure Gap: Why Clinical Pepsin Detection Must Become Standard of Care

The science described in this paper is not new. Johnston established receptor-mediated pepsin endocytosis in laryngeal epithelial cells in 2007. Southwood demonstrated pepsin-driven mitochondrial damage in human nasal epithelial cells in 2015. Tasker found pepsin in middle ear effusion fluid in 2002. Nearly two decades have elapsed. The reason this mechanism has not changed clinical practice is not scientific — it is infrastructural. The tools required to detect pepsin in clinical specimens do not exist within the standard clinical laboratory and billing framework that governs day-to-day medical care.

As a practicing rhinologist in a private practice setting, I confront this gap daily. I cannot order a nasal secretion pepsin assay the way I order a culture, a complete blood count, or an allergen panel. There is no CPT code for nasal lavage pepsin quantification. There is no insurance reimbursement pathway for salivary or nasal pepsin testing in the context of CRS evaluation. There is no College of American Pathologists-validated protocol that allows a clinical pathology laboratory to process a nasal secretion specimen for pepsin concentration and return a reportable result. The PepTest salivary pepsin assay, commercially available in the United Kingdom, has no equivalent clinical billing infrastructure in the United States.[22]

The wrong diagnostic standard has compounded this problem. Twenty-four hour pH monitoring became the clinical gold standard for LPR diagnosis because it was available, quantifiable, and reimbursable — not because it measured the right molecule. pH monitoring detects acid. It does not detect pepsin. A patient with predominantly non-acidic or weakly acidic LPR will test negative on pH monitoring despite having active pepsin in their hypopharynx at concentrations sufficient for endocytosis. This patient’s LPR will be dismissed, their nasal pepsin burden will go unmeasured, and their refractory posterior CRS will continue to be attributed to causes that surgical and antimicrobial treatment cannot address.

A normal upper endoscopy is routinely interpreted as evidence that reflux is not clinically significant. This interpretation is mechanistically unjustified in the context of LPR and pepsin-driven upper airway injury. The esophagus is the most protected tissue in the reflux pathway. It tolerates fifty acid reflux episodes per day without visible injury, while the laryngeal mucosa is damaged by as few as four. A gastroenterologist performing a normal EGD on a patient with refractory posterior CRS and suspected LPR, and concluding that reflux is not contributing to that patient’s disease, is applying the wrong tissue standard to the wrong question. Until gastroenterology and otolaryngology reach a shared understanding that extra-esophageal pepsin injury operates independently of esophageal mucosal damage, patients with PSS will continue to be reassured by a normal scope result that does not speak to their actual disease.

The clinical infrastructure agenda this paper calls for is specific. Validation of a standardized nasal secretion pepsin assay suitable for clinical pathology laboratories, with defined reference ranges. CPT code development for nasal lavage and salivary pepsin quantification. Insurance coverage pathways for pepsin testing in the diagnostic evaluation of refractory CRS, LPR, recurrent pediatric otitis media with effusion, and laryngeal dysplasia. Development of tissue pepsin immunohistochemistry as a clinical pathology service. And a joint statement from the American Academy of Otolaryngology — Head and Neck Surgery and the American College of Gastroenterology acknowledging that a normal EGD does not rule out clinically significant extra-esophageal pepsin injury and that the appropriate diagnostic standard for LPR-driven upper airway disease requires pepsin detection rather than acid detection alone.

None of these infrastructure items requires new science. The science is done. What is required is the institutional will — in otolaryngology professional societies, in clinical pathology, in payer organizations, and in the gastroenterology community — to translate two decades of peer-reviewed mechanistic research into the clinical tools that practicing physicians need to identify pepsin-driven disease in the patients sitting in front of them.